Key statistics dashboard for Korro Bio, Inc. (KRRO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Stock Data
| Price | $13.83 |
| Market Cap | $138M |
| Enterprise Value | $155.0M |
| Beta | 2.43 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -1.41 |
| Price / Book | 2.40 |
| P/S | 58.79 |
| EV/EBITDA | -2.15 |
| EV/Sales | 65.06 |
| EV/FCF | -2.27 |
| P/FCF | -2.05 |
| Earnings Yield | -43.77% |
| FCF Yield | -49.59% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 72.75% |
| EBIT Margin | -3127.20% |
| EBITDA Margin | -3019.19% |
| Operating Margin | -3176.57% |
| Net Margin | -4477.08% |
| Return on Equity | -114.26% |
| Return on Assets | -65.25% |
| Return on Invested Capital | -49.21% |
| Return on Capital Employed | -50.17% |
Financial Health
| Current Ratio | 9.55 |
| Quick Ratio | 9.55 |
| Cash Ratio | 1.97 |
| Debt / Equity | 0.41 |
| Debt / Assets | 25.83% |
| Net Debt / EBITDA | -0.24 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.14 |
| Book Value per share | 5.86 |
| Cash per share | 6.53 |
| FCF per share | -3.87 |
| Tangible Book Value per share | 5.86 |
| Dividend per share | 0.00 |
Related companies: ALT · AMRN · ANNX · ANRO · AURA · DBVT · ENGN
Explore sector: Healthcare · Biotechnology
More sections of KRRO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks